Imfinzi plus kemoterapi minskade risken för död med 20% i 1a linjen vid gallvägscancer
Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer
TOPAZ-1 is the first Phase III trial to show improved survival with an immunotherapy combination in this setting.
Combination did not increase discontinuations due to adverse events vs. chemotherapy alone.
Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer (BTC).
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
